Site investigator perspectives on exclusionary determinations of SWEDDs (Scans Without Evidence of Dopaminergic Deficit) during screening in the SURE-PD3 study
Objective: To assess investigators’ level of agreement with centrally adjudicated SWEDDs based on dopamine transporter imaging (qualitatively defined) during screening of subjects whom investigators had…Among Parkinson’s disease patients with both OFF and dyskinesia, ADS-5102 (amantadine) extended-release reduces disruptive motor episodes and improves function: Analysis of phase 3 trials
Objective: Evaluate the effects of ADS-5102 (amantadine) extended release capsules on motor complications and functional outcomes among patients experiencing both troublesome dyskinesia and OFF (disruptive…Clinical Implication of Stimulus Induced Dyskinesia in Pallidal Deep Brain Stimulation for Advanced Parkinson’s Disease
Objective: To investigate the influence of stimulus induced dyskinesia (SID) on the therapeutic outcome of globus pallidus internus (GPi) deep brain stimulation (DBS) for the…PASADENA: A Phase 2 study to evaluate the safety and efficacy of prasinezumab in early Parkinson’s disease; Part 1 Week-52 results
Objective: Evaluate efficacy and safety of prasinezumab following 52 weeks of treatment in participants with early Parkinson’s disease (PD). Background: Prasinezumab is a humanized monoclonal…Researches on the correlation between wearable device data and UPDRS scores in patients with Parkinson’s disease
Objective: To collect spatiotemporal parameter information of motor symptoms in patients with Parkinson's disease (PD) using wearable device, and analyze its correlation with the Unified…Randomized, placebo-controlled study investigating the safety, pharmacokinetics and efficacy of inhaled apomorphine in Parkinson’s disease patients
Objective: To evaluate the safety, pharmacokinetics (PK) and efficacy of single-dose apomorphine inhalation in PD patients. Background: Apomorphine is a dopamine agonist, approved for treating…Refining Knowledge on the Treatment of Pisa Syndrome with Botulinum Toxin
Objective: To analyze the efficacy of botulinum toxin (BoNT) in cases of pisa syndrome (PS) associated with Parkinson's disease (PD) targeting paraspinal muscles ipsilateral to…Deep Brain Stimulation as the Only Advanced Therapy Available in the Dominican Rebublic, Report ot Two Cases in Centro Cardio Neuro Oftalmologico Y Transplante (Cecanot)
Objective: To describe the evolution of two cases of Parkinson's disease treated with deep brain stimulation in CECANOT. Background: Parkinson's disease is the second most…Impact of dopamine 2/3 receptor agonists on the phenomenology of L-DOPA-induced dyskinesia in patients with Parkinson’s disease
Objective: To investigate possible differences in phenomenology and temporal profile of dyskinesias in patients with Parkinson’s disease (PD) after challenge doses with levodopa alone or…Anti-parkinson effect of natural L-DOPA containing drug Mucuna pruriens against the rotenone induced rat model of Parkinson’s disease
Objective: The nanoherbaceutical formulation comprising natural L-DOPA from Mucuna pruriens against rotenone caused Parkinson's disease in rats to be prepared and evaluated. Background: Parkinson's disease…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 149
- Next Page »